Neurocrine Biosciences (NBIX) News Today

Healthcare of Ontario Pension Plan Trust Fund trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 69.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,660 shares of the company's sto

Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday.

Seven Eight Capital LP cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 76.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,672 shares of the company's stock after selling 5,543 sh

Neurocrine Biosciences (NASDAQ:NBIX) will be releasing earnings before the market opens on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=495472)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-three brokerages that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rat

Vanguard Group Inc. grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,930,926 shares of the company's stock after buying an additional 220,59

Edgestream Partners L.P. raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 71.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,005 shares of the company's s

M&G Plc acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 69,026 shares of the company's stock, valued at approximately $9,526

Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 34.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,19

StockNews.com raised shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Friday.

Sei Investments Co. lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 25.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 86,669 shares of the company's stock a

Motley Fool Asset Management LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 337.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,188 shares of the company's stock after buying an addi

Inspire Investing LLC increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 96.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,296 shares of the company's stock after p

Swiss National Bank decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 294,200 shares of the compan

Forsta AP Fonden boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 94.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,200 shares of the company's stock after acquirin

Morgan Stanley upped their price target on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an "overweight" rating in a research report on Friday.

Neurocrine Biosciences (NASDAQ:NBIX) Reaches New 52-Week High After Analyst Upgrade

Mediolanum International Funds Ltd acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 9,804 shares of the company's stock, valued at

JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $169.00 to $173.00 and gave the company an "overweight" rating in a research report on Wednesday.

Central Pacific Bank Trust Division bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,300 shares of the company's stock, valued at approximatel

Jennison Associates LLC reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 23.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 345,446 shares of the company's stock after selling 106,016 shares during t

Tobam cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 21.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 178,253 shares of the company's stock after selling 48,588 shares during the period.

BNP Paribas Financial Markets grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 431,982 shares of the company's stock after acquiring a

Van ECK Associates Corp grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1,325.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,243 shares of the company's stock after purchasing an additional 85,772

Allspring Global Investments Holdings LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 23.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 506,666 shares of the company's stock af

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Julie Cooke sold 10,000 shares of the business's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the completion of the sale, the insider now directly owns 18,202 shares of the company's stock, valued at $2,551,738.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Chesley Taft & Associates LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,500 shares of the company's sto

Vanguard Group Inc. grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,710,328 shares of the company's stock after buying an additional

Los Angeles Capital Management LLC lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 73.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 245,381 shares of the company's sto

Goldman Sachs Group Inc. cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 12.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 691,632 shares of the company's stock after selling 95,323 shares du

Perceptive Advisors LLC boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 270,794 shares of the company's stock after acqu

Parkman Healthcare Partners LLC lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 67.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,116 shares of the company's

StockNews.com cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.

Morgan Stanley reissued an "overweight" rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday.

First Financial Bankshares Inc acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 15,802 shares of the company's stock, v

Braidwell LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 26.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 715,209 shares of the compa

Superstring Capital Management LP acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 29,34